LexBio Therapeutics and Hiteck Announce Strategic Collaboration to Advance Novel Therapies for Inflammatory Disorders
LexBio and Hiteck partner to develop novel drug candidates using AI-driven molecular glue degraders targeting B- and T-cell pathways for immune-related diseases SUZHOU, JIANGSU, CHINA, February 11, 2026 /EINPresswire.com/ -- LexBio Therapeutics …